Introduction
Src-Like-Adaptor 2, also known as SLA2, belongs to the SLAP family of adapter proteins. It plays a crucial role as a receptor-proximal molecule in suppressing T and B cell-mediated immune responses. SLA2 achieves this by inhibiting the mobilization of calcium ions triggered by antigen receptors. Furthermore, SLA2 interacts with the Cas-Br-M (murine) ecotropic retroviral transforming sequence c.
Description
Recombinant SLA2 Human, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 284 amino acids (specifically, amino acids 1 to 261) with a molecular weight of 31 kDa. This protein is expressed with a 23 amino acid His-tag fused at the N-terminus and is purified using proprietary chromatographic techniques.
Physical Appearance
The product is provided as a sterile, filtered solution that is colorless.
Formulation
The SLA2 protein solution is supplied at a concentration of 0.5 mg/ml and is formulated in a buffer containing 20 mM Tris-HCl (pH 8.0), 10% glycerol, and 0.4 M Urea.
Stability
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to store the product frozen at -20°C. To further enhance long-term stability during frozen storage, consider adding a carrier protein such as HSA or BSA to a final concentration of 0.1%. Repeated freezing and thawing of the product should be avoided.
Purity
The purity of the SLA2 protein is determined to be greater than 80.0% by SDS-PAGE analysis.
Synonyms
Src-like-adapter 2, Modulator of antigen receptor signaling, MARS, Src-like adapter protein 2, SLAP-2, SLA2, C20orf156, SLAP2, Src-like-adapter 2 isoform a, Src-like-adaptor 2, C20orf156, MARS, SLAP-2, SLAP2.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMGSLPSR RKSLPSPSLS SSVQGQGPVT MEAERSKATA VALGSFPAGG PAELSLRLGE PLTIVSEDGD WWTVLSEVSG REYNIPSVHV AKVSHGWLYE GLSREKAEEL LLLPGNPGGA FLIRESQTRR GSYSLSVRLS RPASWDRIRH YRIHCLDNGW LYISPRLTFP SLQALVDHYS ELADDICCLL KEPCVLQRAG PLPGKDIPLP VTVQRTPLNW KELDSSLLFS EAATGEESLL SEGLRESLSF YISLNDEAVS LDDA.